On Monday Neurocrine Biosciences (NASDAQ:NBIX) stock price moved downward at -1.2%. Its total market capitalization is $9379521012. Its day lowest price was $101.1 and its hit its day highest price at $104.3. The stock recent volume is 943630 shares in comparison to its average trading volume of 645760 shares. Looking at the stock’s price level on the past 52-week graph, NBIX recorded a 52-week high of $116.26 and its 52-week low of $64.72.
On Nov. 4, 2019, Neurocrine Biosciences (NASDAQ:NBIX) disclosed its financial results for the quarter ended September 30, 2019 and provided an update on the launch of INGREZZA® (valbenazine) and its clinical development programs.
We are pleased that a record number of new patients initiated treatment with INGREZZA as healthcare providers continue to recognize and treat the involuntary movements associated with tardive dyskinesia, said Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences. Our development programs continue to progress including engagement with regulatory agencies on the adult CAH pivotal trial design. We remain focused on providing patients with access to INGREZZA and preparing for the approval of opicapone in the U.S., while investing strategically to position the company as a leading global biopharmaceutical organization.